Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease

NCT01509677 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

AstraZeneca